Efficient Delivery of Structurally Diverse Protein Cargo into Mammalian Cells by a Bacterial Toxin.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Pharmaceutics

• Publication date

  2015-07-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/acs.molpharmaceut.5b00233PMID 26103531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Advances in anticancer immunotoxin therapy.

  2015cited by this paper
• Protein delivery using Cys2-His2 zinc-finger domains.

  2014cited by this paper
• Removing T-cell epitopes with computational protein design

  2014cited by this paper
• Delivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen

  2014cited by this paper
• Anthrax Toxin-Mediated Delivery of the Pseudomonas Exotoxin A Enzymatic Domain to the Cytosol of Tumor Cells via Cleavable Ubiquitin Fusions

  2013cited by this paper
• Rational design of a biomimetic cell penetrating peptide library.

  2013cited by this paper
• Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells.

  2012cited by this paper
• Targeted gene knockout by direct delivery of ZFN proteins

  2012cited by this paper
• Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A

  2012cited by this paper
• Efficient in vitro encapsulation of protein cargo by an engineered protein container.

  2012cited by this paper
• Cellular uptake mechanisms and endosomal trafficking of supercharged proteins.

  2012cited by this paper
• Mechanism of Diphtheria Toxin Catalytic Domain Delivery to the Eukaryotic Cell Cytosol and the Cellular Factors that Directly Participate in the Process

  2011cited by this paper
• Redox-responsive nanocapsules for intracellular protein delivery.

  2011cited by this paper
• Therapeutic potential of anticancer immunotoxins.

  2011cited by this paper
• Imaging the cell entry of the anthrax oedema and lethal toxins with fluorescent protein chimeras

  2010cited by this paper
• Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.

  2009cited by this paper
• Functional Protein Delivery into Neurons Using Polymeric Nanoparticles*

  2009cited by this paper
• Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics

  2009cited by this paper
• Behavior of the deeply inserted helices in diphtheria toxin T domain: helices 5, 8, and 9 interact strongly and promote pore formation, while helices 6/7 limit pore formation.

  2008cited by this paper
• Ligand binding modulates the mechanical stability of dihydrofolate reductase.

  2005cited by this paper
• Comparative studies on the structure and stability of fluorescent proteins EGFP, zFP506, mRFP1, "dimer2", and DsRed1.

  2004cited by this paper
• A survival motor neuron:tetanus toxin fragment C fusion protein for the targeted delivery of SMN protein to neurons.

  2004cited by this paper
• High stability of Discosoma DsRed as compared to Aequorea EGFP.

  2003cited by this paper
• Biodegradable nanoparticles for drug and gene delivery to cells and tissue.

  2003cited by this paper
• A new Antennapedia-derived vector for intracellular delivery of exogenous compounds.

  2001cited by this paper
• Intracellular Delivery of Proteins with a New Lipid-mediated Delivery System*

  2001cited by this paper
• Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment.

  2001cited by this paper
• Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells

  2000cited by this paper
• Probing Pores with Peptide Plugs

  2000cited by this paper
• Diphtheria Toxin Forms Pores of Different Sizes Depending on Its Concentration in Membranes: Probable Relationship to Oligomerization

  1999cited by this paper
• Anthrax toxin fusion proteins for intracellular delivery of macromolecules

  1999cited by this paper
• Identification of residues lining the anthrax protective antigen channel.

  1998cited by this paper
• The N-Terminal Part of the Enzyme Component (C2I) of the BinaryClostridium botulinum C2 Toxin Interacts with the Binding Component C2II and Functions as a Carrier System for a Rho ADP-Ribosylating C3-Like Fusion Toxin

  1998cited by this paper
• Selection of diphtheria toxin active-site mutants in yeast. Rediscovery of glutamic acid-148 as a key residue.

  1997cited by this paper
• Membrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery

  1997cited by this paper
• Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo.

  1996cited by this paper
• Ability of methotrexate to inhibit translocation to the cytosol of dihydrofolate reductase fused to diphtheria toxin.

  1996cited by this paper
• Tight folding of acidic fibroblast growth factor prevents its translocation to the cytosol with diphtheria toxin as vector.

  1992cited by this paper
• A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV.

  1992cited by this paper
• Membrane translocation of diphtheria toxin carrying passenger protein domains

  1992cited by this paper
• Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor.

  1992cited by this paper
• Diphtheria toxin receptor-binding domain substitution with interleukin 6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein.

  1991cited by this paper
• Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol

  1991cited by this paper
• Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells.

  1991cited by this paper
• Cellular uptake of the tat protein from human immunodeficiency virus.

  1988cited by this paper
• Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein.

  1987cited by this paper
• Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin

  1985cited by this paper
• Requirements for the translocation of diphtheria toxin fragment A across lipid membranes.

  1985cited by this paper
• Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage beta.

  1983cited by this paper
• Insertion of diphtheria toxin into and across membranes: role of phosphoinositide asymmetry

  1982cited by this paper
• Diphtheria toxin forms transmembrane channels in planar lipid bilayers.

  1981cited by this paper
• Rapid entry of nicked diphtheria toxin into cells at low pH. Characterization of the entry process and effects of low pH on the toxin molecule.

  1981cited by this paper
• An enzymic method for measurement of glycogen.

  1967cited by this paper
• Effect of diphtheria toxin on protein synthesis: inactivation of one of the transfer factors.

  1967cited by this paper
• STUDIES ON THE MODE OF ACTION OF DIPHTHERIA TOXIN

  1964cited by this paper
• Materials and Methods Figs. S1 to S3 References a Phenylalanine Clamp Catalyzes Protein Translocation through the Anthrax Toxin Pore

  year unknowncited by this paper

• Anthrax Toxin: A Pioneer of Targeted Protein Toxins

  2025cites this paper
• Effective in vivo delivery of diphtheria toxin using protein cage nanoparticles for targeted cancer therapy.

  2025cites this paper
• Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads.

  2025cites this paper
• Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics

  2025cites this paper
• Development of plug-and-deliverable intracellular protein delivery platforms based on botulinum neurotoxin.

  2024cites this paper
• Some Examples of Bacterial Toxins as Tools

  2024cites this paper
• BIOTECHNOLOGICAL SYSTEM FOR THE SEARCH OF SUBSTANCES WITH POTENTIAL ACTIVITY AGAINST CORONAVIRUS

  2024cites this paper
• Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling

  2024cites this paper
• An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies

  2024cites this paper
• Cell type-specific intracellular protein delivery with inactivated botulinum toxin

  2023cites this paper
• Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications

  2023cites this paper
• Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells

  2023cites this paper
• Cell-Type-Specific Intracellular Protein Delivery with Inactivated Botulinum Neurotoxin.

  2023cites this paper
• Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells

  2023cites this paper
• Endosomal escape for cell-targeted proteins. Going out after going in.

  2023cites this paper
• Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms

  2022cites this paper
• The Diphtheria Toxin Translocation Domain Impairs Receptor Selectivity in Cancer Cell-Targeted Protein Nanoparticles

  2022cites this paper
• Novel Cross-Correction–Enabled Gene Therapy for CDKL5-Deficiency Disorder

  2022cites this paper
• Clostridium botulinum C3 Toxin for Selective Delivery of Cargo into Dendritic Cells and Macrophages

  2022cites this paper
• Membrane translocation of folded proteins

  2022cites this paper
• How Do Biomolecules Cross the Cell Membrane?

  2022cites this paper
• Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier

  2021cites this paper
• Bacterial Toxins Escape the Endosome by Inducing Vesicle Budding and Collapse.

  2021cites this paper
• Highly Efficient Method for Intracellular Delivery of Proteins Mediated by Cholera Toxin-Induced Protein Internalization.

  2021cites this paper
• Exploiting the diphtheria toxin internalization receptor enhances delivery of proteins to lysosomes for enzyme replacement therapy

  2020cites this paper
• Selective and Effective Cancer Treatments using Target‐Switchable Intracellular Bacterial Toxin Delivery Systems

  2020cites this paper
• Targeted modulation of E3 ligases using engineered ubiquitin variants

  2020cites this paper
• Toxin-Mediated siRNA Delivery.

  2020cites this paper
• An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth

  2020cites this paper
• Attenuated diphtheria toxin mediates siRNA delivery

  2020cites this paper
• Exploiting toxin internalization receptors to enhance delivery of proteins to lysosomes for enzyme replacement therapy

  2020cites this paper
• Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids

  2020cites this paper
• Attenuated diphtheria toxin mediates siRNA delivery

  2020cites this paper
• Delivering a RAS protease halts tumor growth

  2020cites this paper
• Design and Production of Recombinant TAT Protein Structure, Catalytic Domain of Diphtheria Toxin, and Evaluation of Its Effect on Cell Line

  2019cites this paper
• Peptides derived from a short stretch of diphtheria toxin bind to heparin-binding epidermal growth factor-like growth factor.

  2019cites this paper
• Inhibition of tumor growth by a novel engineered chimeric toxin that cleaves activated mutant and wild-type RAS

  2019cites this paper
• Intracellular Delivery of Human Purine Nucleoside Phosphorylase by Engineered Diphtheria Toxin Rescues Function in Target Cells.

  2018cites this paper
• Polymeric Peptide Mimics for Protein Delivery

  2018cites this paper
• Use of induced pluripotent stem cells to investigate the effects of purine nucleoside phosphorylase deficiency on neuronal development

  2018cites this paper
• Lafora disease — from pathogenesis to treatment strategies

  2018cites this paper
• Adenosine deaminase deficiency: current treatments and emerging therapeutics

  2018cites this paper
• Overcoming Endosomal Entrapment in Drug Delivery.

  2018cites this paper
• Clostridium difficile toxins A and B: Receptors, pores, and translocation into cells

  2017cites this paper
• Cell-penetrating peptides derived from Clostridium difficile TcdB2 and a related large clostridial toxin

  2017cites this paper
• Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants

  2017cites this paper
• Engineering cell signaling modulators from native protein-protein interactions.

  2017cites this paper
• Repurposing bacterial toxins for intracellular delivery of therapeutic proteins

  2017cites this paper
• Intracellular Delivery of Charge-Converted Monoclonal Antibodies by Combinatorial Design of Block/Homo Polyion Complex Micelles.

  2016cites this paper
• Post-modern therapeutic approaches for progressive myoclonus epilepsy.

  2016cites this paper